We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Leucyl-tRNA Synthetase (LARS) Antibodies|
|Reactivity||Human, Mouse (Murine), Rat (Rattus) Alternatives|
ELISA, Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-LARS AntibodyTarget Details LARS Application Details Handling Images
|Purpose||Rabbit IgG polyclonal antibody for Leucyl tRNA synthetase/LARS detection. Tested with WB, Direct ELISA in Human,Mouse,Rat.|
|Cross-Reactivity (Details)||No cross reactivity with other proteins.|
|Characteristics||Rabbit IgG polyclonal antibody for Leucyl tRNA synthetase/LARS detection. Tested with WB, Direct ELISA in Human,Mouse,Rat.|
|Purification||Immunogen affinity purified.|
|Immunogen||E. coli-derived human Leucyl tRNA synthetase/LARS recombinant protein (Q628-Q855).|
|Plasmids, Primers & others|
Target Details LARSProduct Details anti-LARS Antibody Application Details Handling Images back to top
|Alternative Name||LARS (LARS Antibody Abstract)|
Synonyms: Leucine--tRNA ligase, cytoplasmic, Leucyl-tRNA synthetase, LeuRS, LARS, KIAA1352
Background: Leucyl-tRNA synthetase, cytoplasmic is an enzyme that in humans is encoded by the LARS gene. This gene is mapped to 5q32. It encodes a cytosolic leucine-tRNA synthetase, a member of the class I aminoacyl-tRNA synthetase family. The encoded enzyme catalyzes the ATP-dependent ligation of L-leucine to tRNA(Leu). It is found in the cytoplasm as part of a multisynthetase complex and interacts with the arginine tRNA synthetase through its C-terminal domain. A mutation in this gene was found in affected individuals with infantile liver failure syndrome 1. Alternatively spliced transcript variants of this gene have been observed.
|Pathways||EGFR Signaling Pathway|
Application DetailsProduct Details anti-LARS Antibody Target Details LARS Handling Images back to top
Application details: Western blot|0.1-0.5&mu,g/mL Direct ELISA|0.1-0.5&mu,g/mL
Tested Species: In-house tested species with positive results. Other applications have not been tested. Optimal dilutions should be determined by end users.
|Restrictions||For Research Use only|
HandlingProduct Details anti-LARS Antibody Target Details LARS Application Details Images back to top
|Reconstitution||Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.|
|Buffer||Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage||4 °C,-20 °C|
At -20°C for one year. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20 °C for a longer time. Avoid repeated freezing and thawing.